Home Companies Catalysts Deep Dives
UPLIZNA inebilizumab-cdon APPROVED
Drug Profile
ModalityMonoclonal antibody
RouteIV
Therapy AreaR&I
Launch2020-06-11
Peak Sales Est$2000M
Formulations[{"id":"uplizna-iv","doses":"300mg IV Day 1 and Day 15 (loading), then 300mg Q6M","route":"IV","sett
Companies
AMGN (ORIGINATOR)100%
Mechanism: Anti-CD19 monoclonal antibody
Expert: Humanized IgG1 monoclonal antibody targeting CD19 on B cells and plasmablasts. Afucosylated Fc region enhances ADCC-mediated B-cell depletion.
Everyday: Targets and destroys B-cells (a type of immune cell) by locking onto CD19, a protein found on their surface. Removes the immune cells that are producing harmful autoantibodies.
Targets: ["CD19"]
Revenue History
PeriodRevenue ($M)
2024$379M
2025$655M
Q4 2024$101M
Q4 2025$233M
Programs (3)
IndicationStageKey StudyRegional Status
NMOSDAPPROVEDN-MOmentum[{"stage":"APPROVED","region":"US","approval_date":"2020-06-11"},{"stage":"APPRO
gMGAPPROVEDMINT[{"stage":"APPROVED","region":"US","approval_date":"2024-06-21"}]
IgG4-RDAPPROVEDMITIGATE[{"stage":"APPROVED","region":"US","approval_date":"2024-09-20"}]
Notes
KEY GROWTH DRIVER. +73% YoY. Expanding from NMOSD into IgG4-RD (approved), MG, autoimmune hepatitis, CIDP. Acquired via Horizon. Could become $2B+ franchise.
Data from Supabase · Updated 2026-03-24